Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment
Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment
复制标题
DOI：
10.1177/1352458506070946
复制
发表时间：
2006-12-01
影响因子：
5.8
通讯作者：
Ford, H.
中科院分区：
文献类型：
--
作者：
Lily, O.;McFadden, E.;Ford, H.
在利兹多发性硬化（MS）治疗计划（n=210）中，使用自我报告利兹MS生活质量（LMSQoL）量表测量疾病特异性生活质量。结果显示，与“疾病改善”治疗相关的生活质量显著且持续增加。这与扩展残疾状态评分（EDSS）形成对比，EDSS显示没有可测量的改善。LMSQoL评分的增加与基线年龄、疾病持续时间、残疾或既往复发次数无关。复发缓解型和继发进展型MS患者之间，或接受不同产品的患者之间的治疗效果无显著差异。然而，基线时生活质量较差的患者从治疗中获益最多。那些由于进展、副作用或缺乏效果而停止治疗的患者在治疗中的LMSQoL评分显著降低。在这项研究中，LMSQoL量表对变化有反应，并且易于在临床环境中管理。
Disease specific quality of life was measured in the Leeds Multiple Sclerosis (MS) Treatment Programme (n=210) using the self-report Leeds MS Quality of Life (LMSQoL) scale. The results showed a significant and sustained increase in quality of life associated with 'disease modifying' treatment. This contrasts with the Expanded Disability Status Scores (EDSS), which showed no measurable improvement. An increase in the LMSQoL score did not correlate with baseline age, disease duration, disability or number of prior relapses. There was no significant difference in treatment effect between relapsing-remitting and secondary progressive MS patients, or between patients receiving different products. However, patients with a poor quality of life at baseline showed the most benefit from treatment. Those who had their treatment stopped due to progression, side-effects or lack of effect had significantly lower LMSQoL scores on treatment. In this study, the LMSQoL scale was responsive to change and was easy to administer in a clinical setting.